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Background: Because of symptoms, people with lumbar spinal stenosis (LSS) are often inactive, and this sedentary
behaviour implies risk for diseases including obesity. Research has identified body mass index as the most powerful
predictor of function in LSS. This suggests that function may be improved by targeting weight as a modifiable factor. An
e-health lifestyle intervention was developed aimed at reducing fat mass and increasing physical activity in people with LSS.
The main components of this intervention include pedometer-based physical activity promotion and nutrition education.
Methods/Design: The Spinal Stenosis Pedometer and Nutrition Lifestyle Intervention (SSPANLI) was developed and
piloted with 10 individuals. The protocol for a randomized controlled trail comparing the SSPANLI intervention to usual
non-surgical care follows. One hundred six (106) overweight or obese individuals with LSS will be recruited.
Baseline and follow-up testing includes dual energy x-ray absorptiometry, blood draw, 3-day food record, 7-day
accelerometry, questionnaire, maximal oxygen consumption, neurological exam, balance testing and a Self-Paced
Walking Test. Intervention: During Week 1, the intervention group will receive a pedometer, and a personalized consultation
with both a Dietitian and an exercise specialist. For 12 weeks participants will log on to the e-health website to access
personal step goals, walking maps, nutrition videos, and motivational quotes. Participants will also have access to in-person
Coffee Talk meetings every 3 weeks, and meet with the Dietitian and exercise specialist at week 6. The
control group will proceed with usual care for the 12-week period. Follow-up testing will occur at Weeks 13 and 24.
Discussion: This lifestyle intervention has the potential to provide a unique, non-surgical management option for people
with LSS. Through decreased fat mass and increased function, we may reduce risk for obesity, chronic diseases of inactivity,
and pain. The use of e-health interventions provides an opportunity for patients to become more involved in managing
their own health. Behaviour changes including increased physical activity, and improved dietary habits promote overall
health and quality of life, and may decrease future health care needs in this population.
Trial registration: Clinicaltrials.gov, NCT01902979
Keywords: Lumbar spinal stenosis, Physical activity, Nutrition, Pedometer, Obesity, Exercise, Inactivity, TreatmentBackground
Lumbar spinal stenosis (LSS) is a degenerative condition
which typically affects adults in their sixth and seventh
decades of life [1]. The estimated prevalence of symp-
tomatic LSS ranges between 8.4% [2] and 9.3% in the
general population, [3] and is on the rise worldwide [4].* Correspondence: clane@mtroyal.ca
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symptomatic LSS at any given point in time [2].
LSS is characterized anatomically by a narrow spinal
canal and/or narrow nerve root foramina, resulting from
degenerative changes in the spine. The most specific
symptom of LSS is neurogenic claudication, which in-
cludes pain, numbness and weakness in the low back, but-
tocks and legs brought on by standing and exacerbated by
walking [5]. Because of these symptoms, people with LSS
avoid walking and exhibit sedentary behaviour [6]. Therefore,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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erable impact on risk for chronic diseases of inactivity.
Sedentary behaviour has important implications for
overall health in the LSS population [7,8]. Physical in-
activity and accompanying weight gain increase the risk
of many chronic diseases, notably obesity, metabolic
syndrome, coronary heart disease, type 2 diabetes, and
certain cancers [9-22]. A growing body of literature
also supports a link between obesity-related systemic
inflammation and musculoskeletal pain [15-19,21,22].
In particular, relationships have been established be-
tween low back pain and both fat mass, [23] and body
mass index (BMI) [24-30]. Specific to physical activity,
a recent study identified BMI as the strongest predictor
of day to day function in people with LSS [31]. BMI
was a stronger predictor of function than both disease
severity and pain. This suggests that by targeting
weight as a modifiable factor in people with lumbar
spinal stenosis, we may also impact function. It is pos-
sible that by decreasing fat mass and increasing phys-
ical activity, we can reduce systemic inflammation and
decrease the risk of obesity-related diseases, including
pain, in people with LSS.
Despite the potential implications of weight gain and
inactivity in LSS, to our knowledge there has been no re-
search to date examining non-surgical options for weight
management in overweight and obese individuals with
this condition. The present study aims to address this
gap by evaluating a newly developed lifestyle interven-
tion aimed at promoting weight loss in LSS through
behaviour change techniques, pedometer-based physical
activity promotion, and nutrition education. In keeping
with recent trends in medicine, this program was devel-
oped using an e-health (online) platform. The use of e-
health interventions provides an opportunity for patients
to play an active part in management of their own
health, in co-operation with healthcare providers. This
intervention has the potential to provide a unique,
non-surgical management option for people with LSS,
decreasing the risk for obesity, chronic diseases of
inactivity, and musculoskeletal pain through decreased
fat mass and increased physical activity.
Objective
The objective of this study is to evaluate an e-health life-
style intervention aimed at increasing physical activity,
decreasing fat mass, and increasing quality of life in
overweight and obese people with LSS. The main com-
ponents of this intervention consist of pedometer-based
physical activity promotion and nutrition education.
Methods/Design
The project consists of three phases. Details regarding
Phases 1 (program development) and 2 (interventionpilot) have been submitted in a separate publication and
will not be presented here.
Phase 1, development (Complete)
Develop the online (e-health) intervention tool used to
deliver weekly personalized pedometer step goals and
tips, as well as nutrition education sessions.
Phase 2, intervention pilot (Complete)
Over the past 2 years, the Spinal Stenosis Pedometer
and Nutrition Lifestyle Intervention (SSPANLI) was de-
veloped and piloted with 10 overweight and obese indi-
viduals with LSS. This pilot data was used to evaluate
the efficacy, content and feasibility of the intervention.
Based on feedback obtained during post-pilot interviews,
the intervention was shown to be feasible and attractive
to participants. Statistically significant improvements
were observed for fat mass (dual x-ray absorptiometry:
DXA), trunk fat mass (DXA), physical function (accel-
erometry), symptom severity (Swiss Symptom Severity
Scale), caloric intake (DA plus 10.0), and mental health
(SF-36). Publication of the pilot data is forthcoming.
Phase 3
The final phase in this project, described here, is a fully
powered randomized controlled trial comparing the
Spinal Stenosis Pedometer and Nutrition Lifestyle Inter-
vention (SSPANLI) to usual care for lumbar spinal sten-
osis. Recruitment for the trial began in August 2013.
Ethics approval for the trial was obtained through the
Conjoint Health Research Ethics Board of the University
of Calgary.
Study design and overview
The Spinal Stenosis Pedometer and Nutrition Lifestyle
Intervention (SSPANLI) is a single-blind RCT comparing
the SSPANLI intervention to usual non-surgical care for
LSS. This project will evaluate the new e-health lifestyle
intervention aimed at decreasing fat mass, increasing
physical activity and improving quality of life in older
adults with LSS who are overweight or obese. The
SSPANLI protocol includes individualized pedometer-
based activity recommendations and online nutrition
education tools, as well as two personalized consulta-
tions with a Registered Dietitian and exercise specialist.
Figure 1 presents a flowchart for the study.
Inclusion and exclusion criteria
All participants will be at least 45 years of age and will
have received a diagnosis of LSS by a spine surgeon who
has both examined the patient and reviewed imaging re-
sults (magnetic resonance imaging or computed tomog-
raphy). All participants will be required to have a BMI of
25 kg/m2 or greater (overweight) and to have maintained
Information provided by study personnel
Person decides not 
to participate (n=50)
Add to running tally 
of number of people 
who opted out
Person is willing to 
participate (n=150)
Identify potential subjects (n=200)
Eligibility screen completed 
by study coordinator
Ineligible according to inclusion/exclusion criteria or 
not interested: Add to running tally of ineligible 
people with explanation (n=44)
Control Group (n=53)
Randomization to control or intervention group
Baseline testing (2 visits) (same as intervention group)
Intervention Group (n=53)
Baseline Testing Visit 1 at University of Calgary 
Human Performance Lab (Week -1)
Participant is instructed to continue with their normal 
routine for the 12-week intervention period
E-HEALTH INTERVENTION (Weeks 1-12): Includes online 
access to weekly pedometer step goal, exercise tips, walking 
maps, nutrition education videos, inspirational quotes, Coffee 
Talk meeting information and archives.
6-week Check-in meeting with Dietician and 
Exercise Physiologist (Week 6)
5 subjects discontinued participation: Explanation 
recorded if possible
Follow-up testing Visits 1 and 2 (Week 13)
Data Analysis and Dissemination
Baseline Testing Visit 2 (Week 1) at Mount Royal 
University, including meeting with Registered 
Dietician and Exercise Physiologist. Participants
provided with pedometer and website instructions. 
Follow-up testing at Visits 3 and 4 (Week 24) (n=88)
8 subjects (4 from each group) lost to follow-up: 
Explanation recorded if possible
Eligible to 
participate (n=106)
5 subjects lost to follow-up or discontinued 
participation: Explanation recorded if 
possible
Figure 1 Study flowchart.
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sion criteria include diagnosed eating disorders, preg-
nancy, weight over 350 lbs, or any co-morbid conditions
that would limit walking significantly or make participa-
tion in a walking program medically inadvisable, includ-
ing severe arthritis, neuropathy or other neuromusculardisease, angina, cardiovascular disease, pulmonary disease,
stroke or other neurological disorder, or peripheral vas-
cular disease. Participants currently participating in a diet
or lifestyle intervention for weight loss, who are on medi-
cations or herbal preparations known to influence body-
weight (including, but not limited to antidepressants and
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lipid-lowering or diabetes medications over the past
3 months will be excluded.
Recruitment
All participants will be recruited through the University
of Calgary Spine Program and Caleo Health. Spine pa-
tients are referred to Caleo Health Centre for a complete
spine assessment to determine the most appropriate
treatment (referral to a surgeon, physical medicine,
physiotherapy, combination therapy etc.). It is through
this triage process that the research nurse will be able to
identify potential participants and contact them for pos-
sible participation in the trial. Spine surgeons from the
University of Calgary Spine Program will also be made
aware of this protocol, so that that their patient popula-
tions can be reviewed for potential inclusion. In the
triage process, a review of the medical history including
height and weight will be obtained (used to determine
BMI). This information will be documented on both a
triage form as well as documentation provided to the re-
ferring doctor. This information will be reviewed by the
research nurse (who currently reviews all triage forms).
Potential patients will either be contacted by phone or
seen the day of the clinic visit to discuss the study. A
screening form will be used to identify potential partici-
pants based on inclusion/exclusion criteria.
Blinding and randomization
After completing the screening process participants will
be randomly assigned to either the intervention group
(n = 53) or the control group (n = 53). A computer-
generated randomization sequence produced using R
statistical analysis program will be used. Participants will
be allocated to the group by the Study Coordinator, and
will be aware of the allocated group. Those assigned to
the control group will be offered the opportunity to try
the intervention once the study is complete. All study
investigators including the statistician, and research staff
collecting data will be blinded to group allocation (single
blind design). Participants will be asked not to comment
to assessors regarding allocation.
Testing schedule
Following enrollment, patients will begin the study
protocol, which involves 7 testing appointments over a
6 month period. These appointments include Baseline
Visit 1 (week −1), Baseline Visit 2 (week 1), 6-week check-
in (week 6), Follow-up Visits 1 and 2 (week 13) and
Follow-up Visits 3 and 4 (week 24). The intervention be-
gins at Baseline Visit 2 and runs for 12 weeks (weeks 1–12).
Enrollment will be continuous throughout the study.
Once patients are enrolled they will begin assessments at
the next available scheduled date for Baseline Visit 1. Six-week check-in sessions will be arranged individually
for each participant. The primary outcomes at each
time point will be fat mass (%), steps/day, and quality
of life (SF-36).
Baseline testing and intervention
Baseline testing will take place over two visits. During
the second baseline visit, components of the interven-
tion will be introduced.
Baseline visit 1
During Baseline Visit 1, anthropometric measurements
of height, weight and waist circumference will be taken.
To assess body composition participants will undergo
dual energy x-ray absorptiometry (DXA) testing. The
DXA scan uses a low emission x-ray in conjunction with
Hologic software to provide measurements for lean
mass, fat mass and bone mineral density (Hologic QDR
4500, Hologic, Inc., Bedford, MA).
Blood collection
All blood draws will be performed after an 8 hour over-
night fast by a trained nurse or phlebotomist. 2 ml of
blood will be collected with sodium fluoride for glucose
analysis. A further 3 ml of blood will be collected in
serum tubes for adipokine analysis (adiponectin, c-
reactive protein (CRP), leptin, IL-1β, IL-6, IL-8, TNF-α,
MCP-1 and insulin). A final 4 ml will be collected for
serum lipid analysis. Samples will be centrifuged and
stored at −80°C until analysis.
Plasma glucose
Blood glucose concentrations will be measured in tripli-
cate using a glucose trinder assay kit (Stanbio Laboratory,
Boerne, TX). Serum Adipokines: Adiponectin will be mea-
sured in duplicate using an ELISA kit from Millipore
(Millipore, Billeerica, MA). For leptin, IL-1β, IL-6, IL-8,
TNF-α, MCP-1 and insulin duplicates samples of 25 μl of
serum will be analyzed using a Milliplex MAP Human
Serum Adipokine Panel B kit (Millipore, Billerica, MA).
CRP will be measured by Calgary Laboratory Services
(Calgary, AB). Serum lipids: 1.5 ml of serum will be sent
to Calgary Laboratory Services for quantification (total
cholesterol, HDL cholesterol, LD cholesterol and triglyce-
rides will be calculated).
7-day activity monitoring
Participants will be provided with an activity monitor
(Actigraph GT3X, Actigraph LLC, Pensacola, FL.) and an
activity log. Participants will be instructed to wear the
monitor during the waking hours, except when in contact
with water. Participants will also be instructed how to
complete a daily log to accompany the activity monitor.
Participants will be asked to wear the monitor for the
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activity level (steps per day). The activity monitor can
provide an objective record of frequency, intensity, and
duration of physical activity with minimal burden on par-
ticipants. The Actigraph is widely accepted in the field as
a valid and reliable means of assessing ambulatory physical
activity [32-36].
3-day food records
Food and beverage intake will be assessed using 3-day
food records. Participants will be trained on how to
complete a 3-day food record by a Registered Dietitian on
their first visit. Participants will then be asked to estimate
portion sizes and record all food and beverages consumed
for 2 weekdays and 1 weekend day. The food record will
be completed in the week following Baseline Visit 1, to
establish baseline dietary intake. Dietary intakes will be
analyzed with Diet Analysis Plus 10.0 software (Thomson
Wadsworth, Toronto, ON).
Participants will be provided with a self-addressed,
stamped envelope to return the activity monitor, activity
log, and 3-day food record to Mount Royal University.
Baseline visit 2
Baseline testing during Baseline Visit 2 will include
questionnaire completion, a Self-Paced Walking Test,
balance testing, a neurological examination, and peak
VO2 exercise test on a cycle ergometer. Intervention
components of Baseline Visit 2 will include a one hour
personalized consultation session with a Registered
Dietitian, and a one hour personalized physical activity
counseling session with an Exercise Physiologist (inclu-
ding instructions regarding how to use the pedometer).
Participants will also be guided through the process of ini-
tial login and navigation of the e-health intervention web-
site, as well as provided with instructions regarding how
to fill out the daily personal log book.
Baseline testing details
Questionnaire The questionnaire will be used to collect
information regarding age, gender and history of back
and leg pain, as well as history of medications, alcohol
use, tobacco use and current work status. The standar-
dized instruments to be used can be found in Table 1.
The questionnaire will be completed online through the
intervention website.
Self-paced walking test All participants will undergo a
standardized Self-Paced Walking Test [46]. This test has
been shown to be a valid criterion measure of walking
capacity in people with LSS. Participants are instructed
to walk continuously at their own pace until they feel
that they have to stop due to symptoms of LSS (or otherreasons) or until a time limit of 30 minutes has been
reached. Participants are asked to indicate when they
first experience a change in symptoms, as well as to in-
dicate the nature of the symptoms (type and location).
Test termination is defined as a complete stop of 3 sec-
onds or more. The following information is collected:
total distance and time walked, time/distance to onset of
symptoms, the nature and location of symptoms (pain,
numbness/tingling, weakness or fatigue), average walk-
ing speed, and the reason for test termination should
they not walk for the full 30 minutes (symptoms of LSS,
fatigue, shortness of breath, dizziness, pain or discomfort
due to co-morbidities). Before and immediately after the
walking test, participants will be asked to rate their
current pain on 100 mm Visual Analog Pain Scales for
back, right leg and left leg, with anchors of 0 (no pain)
and 10 (worst possible pain). VAS scales have been used
often in research with spinal stenosis patients and found
to be psychometrically sound [47,48]. Participants will
also be asked to indicate on a body diagram the location
and nature of their symptoms.
Balance testing Balance will be assessed using a HUR-3
Balance platform. Each participant will be assessed for
20 seconds on each of the following stances (all with
eyes open and a firm surface): double leg stance, tandem
stance with right leg forward, tandem stance with left
leg forward, single leg right, single leg left. For each test,
participants will be asked to place their hands on their
hips and face forward. Balance test results are stored
using the HUR-3 software.
Neurological impairment score [49] Both lower limbs
are tested and five parameters are assessed. Points are
added up to a maximum total score of 33 (with a higher
score indicating less neurological impairment). 1. Ten-
don (myotatic) reflexes in lower limbs, that is, patellar
reflex and Achilles tendon reflex. For each reflex evoked
(using facilitating manoeuvres), the person examined is
given 1 point, potential score 0–4 points. 2. Tactile sen-
sation in lower limbs using a cotton swab. If there is a
dysfunction of tactile sensation in both lower limbs, the
person examined receives 0 points. If there is a dysfunc-
tion of tactile sensation in only one lower limb then the
score is 2 points. If tactile sensation is bilaterally normal,
the score is 4 points. 3. Vibration sensation in the lower
limbs will be assessed using a 128-Hz graduated tuning
fork for optimum accuracy. The vibration threshold is
recorded on a scale from 0 to 8, with the maximum
expressed as 8/8 and minimum 0/8. Vibration sensation
will be recorded at the external ankle. 4. Presence of par-
esis of lower limbs will be assessed by asking the partici-
pant to stand on tiptoe, stand on the heels, and squat.
Each exercise successfully performed scored 1.5 points
Table 1 Standardized questionnaires
Questionnaire Description
Physical Function Scale of Swiss Spinal Stenosis
Questionnaire (PF Scale) [1]
The Physical Function Scale was designed to assess walking capacity in people with LSS. The
score is calculated as the un-weighted mean of the five items in the scale. The resulting possible
scores of 1–4 represent a range from mild to severe limitation in physical function/walking.
Symptom Severity Scale of the Swiss Spinal
Stenosis Questionnaire (SS Scale) [1]
The Symptom Severity Scale of the SSSQ was designed to examine severity of symptoms
related to LSS. It is scored as the un-weighted mean of the seven items in the scale, with scores
from one to seven representing a range from mild to very severe pain.
Oswestry Disability Index (ODI) [37] The ODI is a nine-item questionnaire, which assesses degree of back pain–related disability.
Severity of pain and disability in activities, such as walking, sitting, standing, and personal care,
are rated on Likert scales of five or six points. The ODI was calculated as a percentage of the
total possible score of 53, with a greater score representing greater back pain–related disability.
Short-Form 36 (SF-36) [38] Overall health and disability will be assessed using the 36-Item Short Form Health Survey. Using
the 36 items, the following scales are calculated: General Health, Physical Functioning, Social
Functioning, Role Limitation—Physical, Role Limitation—Emotional, Mental Health, Vitality, and
Bodily Pain. Each scale score is calculated independently using algorithms defined by the
developers.
Centres for Disease Control Depression Scale
(CES-D) [39]
The 20 item Centres for Epidemiologic Studies Depression Scale was designed to assess
depression. It is scored by totaling all item scores, with a higher total indicating greater
depression. Scores range from 0 to 60, with higher scores indicating more symptoms of
depression. CESD scores of 16 to 26 are considered indicative of mild depression and scores of
27 or more indicative of major depression.
Regulation for Eating Behaviors Scale (REBS) [40] To assess healthy eating motives, participants will complete the 24-item Regulation of Eating
Behaviour Scale. Six subscales comprised of 4 items/subscale formulate the REBS including
(a) Amotivation, (b) External Regulation, (c) Introjected Regulation, (d) Identified Regulation,
(e) Integrated Regulation, and (f) Intrinsic regulation. Participants respond to each REBS item on
a 7-point Likert scale anchored at the extremes by (1) ‘Does not correspond at all’ and
(7) ‘Corresponds exactly’.
Behavioral Regulation in Exercise Questionnaire
2-R (BREQ-2R) [41,42]
•To assess exercise motive related to exercise, participants will complete the 19 item Behavioral
Regulation in Exercise Questioniare-2 plus four items assessing Integrated Regulation. The BREQ-2
assesses the following constructs: (a) Amotivation, (b) External Regulation, (c) Introjected Regulation,
(d) Identified Regulation, and (e) Intrinsic Regulation. Reponses to the BREQ-2 and Integrated
Regulation items were made using a 5-point Likert scale anchored at the extremes by 0
(‘Not true for me’) and 4 (‘Very true for me’).
Pain Catastrophizing Questionnaire [43] The PCS was designed to assess pain catastrophizing. The PCS is a 13-item instrument that asks
participants to reflect on past painful experiences, and to indicate the degree to which they
experience each of 13 thoughts or feelings when experiencing pain, on 5-point scales with the
end points (0) not at all and (4) all the time. The PCS total score is computed by summing
responses to all 13 items. PCS total scores range from 0 – 52. A score of 30 or above represents
clinically relevant catastrophizing.
Tampa Scale for Kinesiophobia (TSK) [44,45] The TSK was designed to assess fear of movement (kinesiophobia). The TSK uses a 4-point Likert
scale, with scoring options ranging from 1 = ‘strongly disagree’ to 4 = ‘strongly agree’. A total score
is calculated after inversion of the individual scores of items 4, 8, 12 and 16. The total score ranges
between 17 and 68. A high value on the TSK indicates a high degree of kinesiophobia. A score of
37 differentiates between high and low scores.
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ered as the ability to stand from a full squatting position.
Whenever the results of these tests are in doubt (e.g.,
where the influence of pain or joint arthrosis appeared
possible), the presence of paresis will be verified by
isometric muscle testing. 5. Evaluation of ability to walk
and run. If the participant is able to run at least 10 m,
12 points will be awarded. If the person is able to walk
this distance without support he/she receives 9 points.
Walking with one crutch will score 6 points, walking
with the aid of two crutches will score 3 points. If the
participant is unable to walk, the score will be 0.
VO2peak testing protocol The test administrator will re-
view the participant’s medical history, physical findings andcheck for any absolute contraindications to exercise, or
signs indicative of major cardio-vascular, pulmonary or
metabolic disease. All tests will be conducted by a Certified
Exercise Physiologist or Kinesiologist. Prior to exercise
testing, height and weight will be measured, and 12-lead
electrocardiogram (ECG) electrodes placed. The BORG
scale for perceived exertion (RPE) will be explained to the
participant [50]. Resting heart rate, blood pressure and
ECG readings will be obtained over 4 minutes prior to test-
ing [51-54]. The participant will be set up at the appropri-
ate seat height on an electrically braked cycle ergometer. A
face mask will be connected to a metabolic cart for breath
by breath gas analysis. The ECG will remain connected to
a three channel recorder for ECG, time and ventilation re-
cordings [55]. The following variables will be recorded in
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unloaded cycling, before and after the test, and during the
last 15 seconds of each stage in the incremental protocol
to follow: heart rate, ventilation, volume of oxygen (VO2),
volume of carbon dioxide, and respiratory exchange ratio
(RER) [51,56]. Blood pressure will be measured before and
after the test, as well as in the last 15 seconds of each third
minute [54]. RPE will be measured in the last 15 s of each
third minute. Throughout the test the ECG will be moni-
tored for abnormal changes.
The individualized incremental protocol to be used is
taken from Wasserman et al. [56] and has been found to
produce accurate estimates of VO2 peak [56]. For each
participant, VO2 unloaded is calculated from the partici-
pant’s weight, and VO2peak is estimated from the partici-
pant’s age and height [56]. The work rate increment
necessary to reach the estimated VO2peak in 10 minutes
is calculated. This time limit is chosen because it has
been shown that incremental tests of 6–12 minutes
provide the highest VO2peak for normal participants [56].
1. VO2 unloaded in ml/min = 150 + (6 × weight in kg)
2. VO2 peak in ml/min = (height in cm ‐ age in years) ×
20 for sedentary men and × 14 sendentary women
3. Work rate increment per minute in watts =
(VO2 peak estimate ‐VO2 unloaded estimate)/100
After 4 minutes of unloaded cycling, the calculated
work load is applied increased by that amount every
minute until a symptom limited test endpoint is reached.
Participants will be encouraged to continue until they
feel that for whatever reason, they are unable to. Once
the test is terminated, the participant will continue
unloaded cycling for 4 minutes. The participant will be
asked to indicate what symptoms caused he/she to stop
the test [56]. All variables will continue to be measured
as described during this time. The ECG, blood pressure
and RPE will be monitored every minute until values
return to baseline [52].
VO2peak will be determined as the highest value for
VO2 averaged over a 30 second period [54], and will be
confirmed by any of the following criteria [52]: Failure of
heart rate to increase with increasing load, or achieve-
ment of 85% age predicted max heart rate; a plateau in
oxygen uptake with increasing work-load; RER of >1.15;
RPE > 17 on the BORG scale.
Intervention component details
Components of the intervention can be found in Table 2.
Nutrition counseling and education component
During Baseline Visit 2, each participant will meet with a
Registered Dietitian for an initial nutrition counseling ses-
sion of approximately 1 hour. This session will involve areview of the baseline 3 day food record, suggestions tar-
geting reduced energy intake, and counseling on behaviour
change strategies including goal setting, self-monitoring,
stimulus control, and social support [57]. Each participant
will be provided with methods for 454 a daily caloric
reduction of 500–750 kcal. Each week, participants will log
on to the intervention website to access new nutrition edu-
cation sessions directed at supporting improved nutrition
behaviors, weight loss, and behaviour change.
Physical activity counseling session and promotion component
During Baseline Visit 2, participants will meet with an
exercise specialist to discuss goals, barriers to physical
activity, personal strategies for increasing activity, and
walkability of the participant’s neighbourhood. They will
discuss the results of their VO2 test in relation to goal
setting. Each participant will then receive a pedometer
and a personalized daily step goal for Week 1. Partici-
pants will wear the pedometer daily, during the waking
hours. Each subsequent week, participants will log on to
the intervention website to receive a new individualized
daily step goal. Participants will be instructed to attempt
to meet the step goal in whatever way they feel capable,
and will be provided with new ‘tips’ each week. This
method is thought to be well suited to LSS patients, as
opposed to traditional time or distance goals for walking,
given that participants can accumulate steps in small
bouts throughout the day and within their homes. The
goal will be to increase steps per day by a total of 20%
by the end of the 12 week intervention period. The goal
will be calculated as an increase of 1.3% above baseline
for weeks 1–6 and 2% for weeks 7–12.
Intervention website training
During Baseline Visit 2, each participant will be guided
through the login process for the intervention website,
as well as instructed regarding how to navigate the web-
site. During the initial registration, participants will enter
their baseline daily step count, as determined from the
7-day activity monitoring. This value will be used to
calculate the personalized weekly step goals.
Log book training
During Baseline Visit 2, each participant will be ins-
tructed regarding how to fill out the daily log book. Over
the 12 week intervention period participants will record
the following daily: food and water intake, physical acti-
vity: daily steps as well as duration (minutes) and inten-
sity (mild, moderate or severe) of any structured activity,
sleep (hours), mood, and medications.
12- Week Intervention (at participants’ home)
Starting the day of Baseline Visit 2, each week for 12 weeks
participants will log on to the e-health intervention website
Table 2 Intervention components
Intervention component Purpose
Registered Dietitian Consultations Provides personalized nutrition education and behaviour modification strategies related to dietary intake
Exercise Physiologist Consultations Provides physical activity education and behaviour modification strategies related to physical activity
Personalized step goal and physical activity tips Provides motivation to increase physical activity
Daily wear of pedometer Provides opportunity for self-management and bio-feedback
Nutrition education videos Provides nutrition education for self-management
Log book Provides opportunity for self-management
Coffee Talk Provides social context and peer support
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physical activity goal (steps) and tips regarding how to
achieve this goal. Each week they will also access a nutrition
education video. The nutrition video topics are as follows:
Weight loss – secrets to success; Meal timing and track-
ing; The art of snacking; Environment for success; Food
diaries; Feeling full with fibre and hydration; Be a fat and
calorie detective; Saboteurs to weight loss parts 1 and 2;
Energy density; Mindful eating; and The 10 habits of suc-
cessful weight loss maintainers. Every three weeks there
will be an optional ‘Coffee Talk’ meeting. These meetings
will be casual gatherings meant to provide social context
and support to participants. A member of the study staff
will be present at each Coffee Talk to discuss progress and
ideas. These meetings will be announced through the
intervention website. At any time, participants will be able
to access content from previous weeks via the archives.
6-Week check-in session
The 6-week Check-in session will be at mid-intervention.
Participants will meet with the Registered Dietitian and
Exercise Physiologist for a second time to discuss individual
progress, barriers to success and suggested modifications.
Follow-up
There will be two follow-up testing time points. The first
will be directly following the intervention at 13 weeks
and the second at 24-weeks. Protocols for follow-up test-
ing will be identical to baseline testing with two visits at
each time point. Each follow-up will include a visit to
the University of Calgary Human Performance Lab as
well as a visit to Mount Royal University Exercise
Sciences Lab. At the Human Performance Lab partici-
pants will have DXA testing, anthropometric measure-
ments, a blood draw, and instructions regarding how to
complete the final 7-day activity monitoring and 3 day
food record. At the Exercise Sciences Lab, participants
will complete the follow-up questionnaire, Self-Paced
Walking Test, balance testing, neurological impairment
score and VO2 peak testing. The questionnaire will be
identical to the baseline questionnaire, with the addition
of the change questions. The change questions are on 7-point likert scales and assess perceived change in activity
level, mood, overall health, calorie intake, vegetable
intake and fibre intake.
All participants will be invited back one month after
each follow-up testing session to review their results
with study personnel. Those assigned to the control
group will be offered the opportunity to try the interven-
tion once the study is complete.
Magnetic resonance imaging
Following the 12-week intervention period for each par-
ticipant, we will access the clinical magnetic resonance
imaging (MRI) report. The variables to be extracted
from the MRIs include dural cross sectional area at each
lumbar level, as well as cross-sectional area of the para-
spinal muscles (psoas and multifidus).
Sample size estimate
Pilot study data was used to power the planned RCT.
The pilot study provided an estimate of the variability in
the number of steps taken for 10 participants with LSS.
We used a crude estimate of the sample standard devi-
ation for steps in place of the unknown population
standard deviation. Our main study outcome is number
of steps at the end of the 12-week intervention. For the
pilot study, an average increase of 375 steps was encour-
aged during each six-week period. At the end of the
study, an average increase of 750 steps was anticipated.
This was used to judge whether the intervention was ef-
fective. With α = 0.05 and a mean difference of 750 steps
at the end of study, the standard deviation of the differ-
ence was calculated as follows:





L equals largest and S equals smallest anticipated dif-
ference in the number of steps from baseline to follow-
up period.
The formula for the sample size required, per group,
(with α = 0.05, the probability of type I error, 80% power
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means, μ1 and μ2 with common variance, σ
2, is





2 1:96þ 0:84ð Þ2
750
1250
 2 ¼ 43:60≈44
We concluded that a sample size of 44 people per group
would be needed to detect a between-group difference of
number of steps taken from baseline to week twelve. Based
on the dropout rate for the pilot, we anticipate a potential
dropout rate of 20% for the RCT. We will therefore aim to
recruit 106 participants (53 per group). This number has
been deemed feasible based on the volume of lumbar
spinal stenosis patients seen through the University of Cal-
gary Spine Program (approximately 500 per year).
Statistical analysis
Using the raw quantitative data from the participants of
both groups we will present descriptive statistics sum-
marizing the mean and standard deviation with respect
to all the primary study variables. Age and sex distribu-
tions of the participants will be tabulated. Our goal is to
establish reliable point estimates of the study variables
and to characterize the variability within the two groups.
The independent variable will be the intervention, while
the dependent variables will include steps/day, fat mass (%)
and health related quality of life (SF-36 overall score). Linear
mixed-effects models will be used to determine whether the
changes for each time period (baseline to 13 weeks, baseline
to 24 weeks) were significantly different between intervention
and control groups. Repeated measures analysis of variance
(RANOVA) will be used to examine within group changes
from baseline to 13 weeks and from baseline to 24 weeks.
We will also examine changes in the following vari-
ables: Biochemical markers of obesity and associated co-
morbidities including Plasma glucose, Serum adipokines
(c-reactive protein (CRP), leptin, IL-1β, IL-6, IL-8, TNF-α,
MCP-1 and insulin), and Serum lipids (total cholesterol,
LDL cholesterol, HDL cholesterol and triglycerides);
Physical function (Physical Function Scale of Swiss
Spinal Stenosis Questionnaire); Walking capacity (Self-
Paced Walking Test distance); Balance (mean deviation
from centre of pressure from balance platform); Neuro-
logical impairment (Neurological Impairment Score); Pain
(Symptom Severity Scale and visual analog scales); Back
pain related disability (Oswestry Disability Index); Fear of
movement (Tampa Scale for Kinesiophobia); Depression
(CES-D total score); kilocalorie intake (kcal/day); Fat
intake (grams/day); Vegetable and fruit intake (Canada
Food Guide servings/day); Fibre intake (grams/day); and
Change questions for activity, mood, overall health, calo-
ries, vegetable intake, and fibre intake. Clinical MRIs we
will be used to assess whether imaging findings arepredictive of change in the primary outcome variables fol-
lowing the intervention.
When an inferential test is performed, the level of
significance, α will be set at 0.05, and results will be
presented with p-values. In all tests, p-values less than 5%
(< 0.05) will be considered statistically significant. All
quantitative analyses and hypothesis will be performed
using Minitab software, version 16 5 and R programming
language, version 2.15.1. Specifically, we will use the gee
package, pwr package and samplesize package downloaded
from the Comprehensive R Archive Network (CRAN)
repository for our power and sample size calculations.
Discussion
The estimated cost of LSS in the US exceeds 2 billion dol-
lars annually, with an estimated 2-year cost of $10,486 per
person for non-surgical care, and $88,000 per surgery
[58,59]. There is therefore a need to develop novel and
effective treatments for individuals with this condition
[60,61]. Owing to age and symptom-related mobility limi-
tations, people with LSS are at risk for sedentary behavior
and obesity. Yet, there has been no research to date exam-
ining options for weight management in individuals with
LSS. It is proposed that weight loss could be accomplished
in this population using a recently developed patient-
centered e-health lifestyle modification approach of phys-
ical activity promotion and nutrition education (SSPANLI).
The use of e-health interventions provides an opportun-
ity for patients to become more involved in managing
their own health and wellness. Lifestyle behaviour changes
including increased physical activity, and improved dietary
habits promote overall health and may decrease future
health care needs. Ultimately, improved overall health will
lead to increased functional autonomy and quality of life.
In LSS specifically, weight loss and increased physical
activity can minimize the need for expensive interventions
(e.g. injection and surgery), improve mobility, and reduce
the risk of avoidable health deterioration. It is possible that
by increasing physical activity and decreasing fat mass, we
can modify the risk for diseases of inactivity, including sys-
temic inflammation, metabolic syndrome, type 2 diabetes,
cardiovascular disease. Through reduction of fat mass we
may also reduce the risk for musculoskeletal pain expres-
sion and chronicity. Further, this intervention will support
individuals who require surgery in attaining their recom-
mended pre-surgical weight, as well as reduce the risk of
complications, and revision surgeries. This study is signifi-
cant as it represents the first time an online platform
would be used to deliver a lifestyle intervention aimed at
managing LSS and risk for diseases of inactivity concur-
rently. Because the results of the SSPANLI pilot suggest
that this intervention is feasible, attractive to individuals
with LSS, and effective in a small non-randomized sample,
SSPANLI has the potential to offer an effective, inexpensive,
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North Americans living with LSS today [3].
Abbreviations
LSS: Lumbar spinal stenosis; BMI: Body mass index; DXA: Dual x-ray
absorptiometry; SSPANLI: Spinal stenosis pedometer and nutrition lifestyle
intervention; SF-36: Short Form 36 Questionnaire; ECG: Electrocardiogram;
RPE: Rating of perceived exertion; VO2: Volume of oxygen; MRI: Magnetic
resonance imaging; CRP: C-Reactive protein.
Competing Interests
The authors declare that they have no competing interests.
Authors’ contributions
CTL conceived and designed the study, acquired, analyzed an interpreted
pilot data, and drafted all versions of the manuscript. LL, JP, JR, SM, KS and
RH contributed to design of the study, acquisition and interpretation of pilot
data, and critical revision the manuscript. LM and AK were responsible for
statistical analysis of pilot data and preparation of statistical analysis plans for
the protocol. All authors read and approved the final manuscript.
Acknowledgements
Pilot work used for development of this protocol was funded through the
Mount Royal University Internal Grants program. The randomized trial
described in this manuscript is being funded by the Canadian Institutes for
Health Research (CIHR) through a Catalyst Grant in e-Health Innovations.
Author details
1Department of Physical Education and Recreation Studies, Mount Royal
University, 4825 Mount Royal Gate SW, Calgary, AB T3E 6K6, Canada.
2Department of Nursing, Mount Royal University, 4825 Mount Royal Gate SW,
Calgary, AB T3E 6K6, Canada. 3Department of Physical Therapy, University of
Alberta, 2-50 Corbett Hall, Edmonton, AB T6G 2G4, Canada. 4Southport
Atrium - Cubicle #1510, Alberta Health Services, 10301 Southport Lane SW,
Calgary, AB T2W 1S7, Canada. 5Canadian Memorial Chiropractic College, 19-8
Weston Drive SW, Calgary, AB T3H 5P2, Canada. 6Department of Kinesiology,
Brock University, WC25, 500 Glenridge Ave, St. Catharines, ON L2S 3A1,
Canada. 7Department of Surgery, University of Calgary, Room 0492, McCaig
Tower, Foothills Medical Centre, 3134 Hospital Drive NW, Calgary T2N 5A1,
Canada. 8Office of Research Services, Mount Royal University, Mount Royal
University, 4825 Mount Royal Gate SW, Calgary, AB T3E 6K6, Canada.
Received: 19 September 2013 Accepted: 8 November 2013
Published: 14 November 2013
References
1. Stucki G, Daltroy L, Liang MH, Lipson SJ, Fossel AH, Katz JN: Measurement
properties of a self-administered outcome measure in lumbar spinal
stenosis. Spine 1996, 21:796–803.
2. Kalichman L, Cole R, Kim DH, Li L, Suri P, Guermazi A, Hunter DJ: Spinal
stenosis prevalence and association with symptoms: the Framingham
Study. Spine J 2009, 9:545–550.
3. Ishimoto Y, Yoshimura N, Muraki S, Yamada H, Nagata K, Hashizume H,
Takiguchi N, Minamide A, Oka H, Kawaguchi H, Nakamura K, Akune T, Yoshida
M: Prevalence of symptomatic lumbar spinal stenosis and its association
with physical performance in a population-based cohort in Japan: the
Wakayama Spine Study. Osteoarthritis Cartilage 2012, 20:1103–1108.
4. Deyo RA, Mirza SK: Trends and variations in the use of spine surgery.
Clin Orthop Relat Res 2006, 443:139–146.
5. Porter RW: Spinal stenosis and neurogenic claudication. Spine 1996,
21:2046–2052.
6. Tomkins-Lane CC, Conway J, Hepler C, Haig AJ: Changes in objectively
measured physical activity (Performance) after epidural steroid injection
for lumbar spinal stenosis. Arch Phys Med Rehabil 2012, 93(11):2008–2014.
7. Haslam DW, James WP: Obesity. Lancet 2005, 366:1197–1209.
8. Katzmarzyk PT, Gledhill N, Shephard RJ: The economic burden of physical
inactivity in Canada. CMAJ 2000, 163:1435–1440.
9. Ji RR, Xu ZZ, Strichartz G, Serhan CN: Emerging roles of resolvins in the
resolution of inflammation and pain. Trends Neurosci 2011, 34:599–609.
10. Nathan C, Ding A: Nonresolving inflammation. Cell 2010, 140:871–882.11. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LA, Perretti M,
Rossi AG, Wallace JL: Resolution of inflammation: state of the art,
definitions and terms. FASEB J 2007, 21:325–332.
12. Facchini FS, Hua N, Abbasi F, Reaven GM: Insulin resistance as a predictor
of age-related diseases. J Clin Endocrinol Metab 2001, 86:3574–3578.
13. Cordain L, Eades MR, Eades MD: Hyperinsulinemic diseases of civilization:
more than just Syndrome X. Comp Biochem Physiol A Mol Integr Physiol
2003, 136:95–112.
14. Cowey S, Hardy RW: The metabolic syndrome: a high-risk state for
cancer? Am J Pathol 2006, 169:1505–1522.
15. Shiri R, Karppinen J, Leino-Arjas P, Solovieva S, Viikari-Juntura E: The association
between obesity and low back pain: a meta-analysis. Am J Epidemiol 2010,
171:135–154.
16. Mantyselka P, Miettola J, Niskanen L, Kumpusalo E: Persistent pain at
multiple sites–connection to glucose derangement. Diabetes Res Clin
Pract 2009, 84:e30–e32.
17. Mantyselka P, Miettola J, Niskanen L, Kumpusalo E: Glucose regulation and
chronic pain at multiple sites. Rheumatology (Oxford) 2008, 47:1235–1238.
18. Mantyselka P, Miettola J, Niskanen L, Kumpusalo E: Chronic pain, impaired
glucose tolerance and diabetes: a community-based study. Pain 2008,
137:34–40.
19. Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ: Cardiovascular risk factors
for physician-diagnosed lumbar disc herniation. Spine J 2006, 6:684–691.
20. Berenbaum F: Osteoarthritis as an inflammatory disease (osteoarthritis is
not osteoarthrosis!). Osteoarthritis Cartilage 2013, 21:16–21.
21. Freemont AJ, Peacock TE, Goupille P, Hoyland JA, O’Brien J, Jayson MI:
Nerve ingrowth into diseased intervertebral disc in chronic back pain.
Lancet 1997, 350:178–181.
22. Igarashi A, Kikuchi S, Konno S, Olmarker K: Inflammatory cytokines
released from the facet joint tissue in degenerative lumbar spinal
disorders. Spine 2004, 29:2091–2095. Phila Pa 1976;%.
23. Urquhart DM, Berry P, Wluka AE, Strauss BJ, Wang Y, Proietto J, Jones G,
Dixon JB, Cicuttini FM: Young investigator award winner: increased fat
mass is associated with high levels of low back pain intensity and
disability. Spine 2011, 36:1320–1325. Phila Pa 1976;%.
24. Shiri R, Solovieva S, Husgafvel-Pursiainen K, Telama R, Yang X, Viikari J,
Raitakari OT, Viikari-Juntura E: The role of obesity and physical activity in
non-specific and radiating low back pain: the Young Finns study.
Semin Arthritis Rheum 2013, 42:640–650.
25. Leboeuf-Yde C: Body weight and low back pain: a systematic literature
review of 56 journal articles reporting on 65 epidemiologic studies. Spine
2000, 25:226–237. Phila Pa 1976.
26. Rubin DI: Epidemiology and risk factors for spine pain. Neurol Clin 2007,
25:353–371.
27. Lebovits A, Hainline B, Stone LS, Seminowicz DA, Brunz JT, Rosenquist RW,
Cowan P: Struck from behind: maintaining quality of life with chronic
low back pain. J Pain 2009, 10:927–931.
28. Heuch I, Heuch I, Hagen K, Zwart JA: Body mass index as a risk factor for
developing chronic low back pain: a follow-up in the Nord-Trondelag
health study. Spine 2013, 38:133–139. Phila Pa 1976;%.
29. Heuch I, Heuch I, Hagen K, Zwart JA: Associations between serum lipid
levels and chronic low back pain. Epidemiology 2010, 21:837–841.
30. Heuch I, Hagen K, Heuch I, Nygaard O, Zwart JA: The impact of body mass
index on the prevalence of low back pain: the HUNT study. Spine 2010,
35:764–768. Phila Pa 1976;%.
31. Tomkins-Lane CC, Holz SC, Yamakawa KS, Phalke VV, Quint DJ, Miner J,
Haig AJ: Predictors of walking performance and walking capacity in
people with lumbar spinal stenosis, low back pain, and asymptomatic
controls. Arch Phys Med Rehabil 2012, 93:647–653.
32. Rothney MP, Apker GA, Song Y, Chen KY: Comparing the performance of
three generations of ActiGraph accelerometers. J Appl Physiol 2008,
105:1091–1097.
33. Rothney MP, Schaefer EV, Neumann MM, Choi L, Chen KY: Validity of
physical activity intensity predictions by ActiGraph, Actical, and RT3
accelerometers. Obesity (Silver Spring) 2008, 16:1946–1952.
34. McClain JJ, Sisson SB, Tudor-Locke C: Actigraph accelerometer interinstru-
ment reliability during free-living in adults. Med Sci Sports Exerc 2007,
39:1509–1514.
35. McClain JJ, Craig CL, Sisson SB, Tudor-Locke C: Comparison of Lifecorder
EX and ActiGraph accelerometers under free-living conditions.
Appl Physiol Nutr Metab 2007, 32:753–761.
Tomkins-Lane et al. BMC Musculoskeletal Disorders 2013, 14:322 Page 11 of 11
http://www.biomedcentral.com/1471-2474/14/32236. Corder K, Brage S, Ekelund U: Accelerometers and pedometers: methodology
and clinical application. Curr Opin Clin Nutr Metab Care 2007, 10:597–603.
37. Fairbank JC, Pynsent PB: The Oswestry Disability Index. Spine 2000,
25:2940–2952.
38. Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey
(SF-36): I: conceptual framework and item selection. Med Care 1992,
30:473–483.
39. Radloff LS: The CES-D scale: A self-report depression scale for research in
general populations. Appl Psychol Meas 1977, 1:385–401.
40. Pelletier LG, Dion SC, Slovenic-D’Angelo M, Reid R: Why do you regulate
what you eat? relationship between forms of regulation, eating behav-
iors, sustained dietary behavior change, and psychological adjustment.
Motiv Emot 2004, 48:245–277.
41. Markland D, Tobin V: A modification of the behavioral regulation in
exercise questionnaire to include an assessment of amotivation.
Journal of Sport and Exercise Psychology 2004, 26:191–196.
42. Wilson PM, Rodgers WM, Loitz CC, Scime G: “It’s Who I Am…Really!” The
importance of integrated regulation in exercise contexts. Journal of
Applied Biobehavioural Research 2006, 11:79–104.
43. Sullivan MJL, Bishop S, Pivik J: The pain catastrophizing questionnaire:
development and validation. Psychol Assess 1995, 7:524–532.
44. Swinkels-Meewisse EJ, Swinkels RA, Verbeek AL, Vlaeyen JW, Oostendorp RA:
Psychometric properties of the tampa scale for kinesiophobia and the
fear-avoidance beliefs questionnaire in acute low back pain. Man Ther
2003, 8:29–36.
45. Miller R, Kori S, Todd D: The Tampa Scale for Kinesiophobia. Philadelphia: Ref
Type: Unpublished Work; 1991.
46. Tomkins CC, Battie MC, Rogers T, Jiang H, Petersen S: A criterion measure
of walking capacity in lumbar spinal stenosis and its comparison with a
treadmill protocol. Spine 2009, 34:2449.
47. McCormack HM, Horne DJ, Sheather S: Clinical applications of visual
analogue scales: a critical review. Psychol Med 1988, 18:1007–1019.
48. Zanoli G, Stromqvist B, Jonsson B: Visual analog scales for interpretation
of back and leg pain intensity in patients operated for degenerative
lumbar spine disorders. Spine 2001, 26:2375–2380.
49. Adamova BM, Vohanka S, Hnojcikova M, Okacova I, Dusek L, Bednarik J:
Neurological impairment score in lumbar spinal stenosis. Eur Spine J
2010, 303(13):1259–1265.
50. Borg GA: Psychophysical bases of perceived exertion. Med Sci Sports Exerc
1982, 14:377–381.
51. Wasserman K, Hansen JE, Sue DY, Whipp BJ: Principles of Exercise Testing and
Interpretation. Philadelphia: Lea and Febiger; 1987.
52. Fanuele JC, Birkmeyer NJ, Abdu WA, Tosteson TD, Weinstein JN: ACSM’s
guidelines for exercise testing and prescription, ed 6th. Philadelphia: Lippincott
Williams and Wilkins; 2000.
53. American College of Sports Medicine: ACSM’s guidelines for exercise testing
and prescription. Philadelphia: Lippincott Williams and Wilkins; 1991.
54. American College of Sports Medicine: ACSM’s guidelines for exercise testing
and prescription, ed 7th. Philadelphia: Lippincott Williams and Wilkins; 2006.
55. Jones NL: Clinical Exercise Testing, ed Fourth. Philadelphia: W. B. Saunders
Company; 1997.
56. Wasserman K, Hansen JE, Sue DY, Stringer WW, Whipp BJ: Principles of
Exercise Testing and Interpretation, ed 4th. Philadelphia: Lippincott Williams
and Wilkins; 2005.
57. Spahn JM, Reeves RS, Keim KS, Laquatra I, Kellogg M, Jortberg B, Clark NA:
State of the evidence regarding behavior change theories and strategies
in nutrition counseling to facilitate health and food behavior change.
J Am Diet Assoc 2010, 110:879–891.
58. Deyo RA, Mirza SK, Martin BI, Kreuter W, Goodman DC, Jarvik JG: Trends,
major medical complications, and charges associated with surgery for
lumbar spinal stenosis in older adults. JAMA: the journal of the American
Medical Association 2010, 303:1265.
59. Parker SL, Zuckerman S, Shau D, Mendenhal S, Godil SS, McGirt M: 135
Comprehensive medical management of lumbar stenosis and
spondylolisthesis is not effective in real-world care: a value analysis of
cost, pain, disability and quality of life. Neurosurgery 2012, 71:E554–E555.60. Ciol MA, Deyo RA, Howell E, Kreif S: An assessment of surgery for spinal
stenosis: time trends, geographic variations, complications, and
reoperations. J Am Geriatr Soc 1996, 44:285–290.
61. Fanuele JC, Birkmeyer NJ, Abdu WA, Tosteson TD, Weinstein JN: The impact
of spinal problems on the health status of patients: have we
underestimated the effect? Spine 2000, 25:1509–1514.
doi:10.1186/1471-2474-14-322
Cite this article as: Tomkins-Lane et al.: The spinal stenosis pedometer
and nutrition lifestyle intervention (SSPANLI) randomized controlled trial
protocol. BMC Musculoskeletal Disorders 2013 14:322.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
